Krystal Biotech’s Strategic Advancements and Financial Health Justify Buy Rating

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Krystal Biotech (KRYS – Research Report) today and set a price target of $240.00.

Joseph Pantginis has given his Buy rating due to a combination of factors surrounding Krystal Biotech’s strategic advancements and financial health. The company has demonstrated resilience with a strong cash position of $765.3 million, despite a slight dip in first-quarter revenue, which was anticipated due to industry trends. The management’s proactive approach in enhancing their sales force to address temporary slowdowns in new patient starts reflects their commitment to maintaining growth momentum.
Furthermore, Krystal Biotech’s robust pipeline, with four significant clinical readouts expected by the end of 2025, underscores its potential for future success. The recent FDA clearance for KB801, aimed at treating neurotrophic keratitis, highlights the company’s innovative approach in the ophthalmic field. This development, alongside the planned launches of VYJUVEK in key international markets, positions Krystal Biotech for substantial growth, justifying the Buy rating from Joseph Pantginis.